Please login to the form below

Not currently logged in

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

Gilead Sciences

MacroGenics could receive up to $1bn as part of a new deal with Gilead to research antibodies for four undisclosed targets.

Driving the deal's high value is MacroGenics' promising dual-affinity re-targeting (DART) technology, which Gilead will be hoping to harness in its quest to producing antibody-based therapies that can simultaneously target two different antigens.

The technology's promise has already seen MacroGenics sign a number of pharma deals, tying up with the likes of Boehringer Ingelheim and Servier, and the US-based biotech said it expects the first investigational new drug application for a compound developed using DART to be submitted in late 2013.

The latest agreement involves four targets in total, with Gilead to hold exclusive worldwide rights for three of the programmes.

For the remaining programme, Gilead will hold development and commercialisation rights in North America, Europe, Australia and New Zealand, with MacroGenics retaining rights in all other markets, including Japan, China and Russia.

In financial terms, Gilead will fund research activities in all four programmes in addition to a total of up to $30m in license fee payments and up to $85m in pre-clinical milestone payments.

However, MacroGenics said the total value of the deal could top $1bn if all four programmes achieve the relevant clinical, regulatory and commercialisation milestones.

“We are very pleased to enter this collaboration with Gilead, a world-class biopharmaceutical company committed to the development of innovative therapeutics,” said Dr Scott Koenig, president and CEO of MacroGenics.

“As the fourth major collaboration around our DART platform in the past two years, this deal represents the latest validation of our ongoing efforts."

10th January 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...